EASTONBIOPHARMACEUTICALS(SH:688513)2023-10-26 16:00Financial Performance - The company's operating revenue for Q3 2023 was CNY 294,422,090.50, a decrease of 8.62% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was CNY 62,194,392.73, reflecting a year-on-year increase of 2.20%[5]. - The net profit after deducting non-recurring gains and losses was CNY 46,364,976.64, which is an increase of 20.37% year-on-year[5]. - Total operating revenue for the first three quarters of 2023 was ¥849,780,066.91, a decrease of 5.3% compared to ¥897,590,018.32 in the same period of 2022[19]. - Net profit for the first three quarters of 2023 was ¥193,716,138.10, slightly down from ¥195,492,474.81 in the same period of 2022, representing a decrease of 0.9%[20]. - Basic and diluted earnings per share for the first three quarters of 2023 were both ¥1.61, compared to ¥1.63 in the same period of 2022[21]. Assets and Liabilities - The total assets at the end of the reporting period reached CNY 3,215,971,354.38, representing a growth of 6.58% compared to the end of the previous year[6]. - As of September 30, 2023, the company's total assets amounted to RMB 3,215,971,354.38, an increase from RMB 3,017,540,233.11 at the end of 2022, reflecting a growth of approximately 6.55%[14]. - The company's total liabilities rose to RMB 644,305,849.48 from RMB 573,080,516.96, marking an increase of around 12.42%[16]. - The total equity attributable to shareholders at the end of the reporting period was CNY 2,571,665,504.90, up by 5.20% from the previous year[6]. - The company's equity attributable to shareholders increased to RMB 2,571,665,504.90 from RMB 2,444,459,716.15, reflecting a growth of approximately 5.19%[16]. Cash Flow - The cash flow from operating activities for the year-to-date period was CNY 197,748,590.40, showing an increase of 39.90%[9]. - Cash flow from operating activities for the first three quarters of 2023 was ¥197,748,590.40, an increase of 39.9% from ¥141,346,062.05 in the previous year[24]. - The net cash flow from investing activities was -$532.55 million, an improvement from -$673.66 million in the previous period[25]. - Cash inflow from financing activities totaled $175 million, compared to $147.37 million in the prior period[25]. - The net cash flow from financing activities was $34.58 million, down from $52.19 million year-over-year[25]. - The net increase in cash and cash equivalents was -$300.23 million, compared to -$479.99 million in the previous year[25]. - The ending balance of cash and cash equivalents was $521.63 million, down from $555.90 million in the prior period[25]. Expenses - Research and development expenses for Q3 2023 amounted to CNY 62,832,043.28, which is a decrease of 17.08% year-on-year[6]. - Research and development expenses for the first three quarters of 2023 were ¥168,765,644.63, slightly up from ¥165,078,988.64 in the same period of 2022[19]. - Sales expenses decreased to ¥287,131,932.10 in the first three quarters of 2023, down 21.5% from ¥365,827,205.65 in the previous year[19]. Shareholder Information - The company reported a total of 4,309 ordinary shareholders at the end of the reporting period[10]. - The company has a total of 120,090,000 shares outstanding, all of which are freely tradable as of September 4, 2023[13].